Cipla Patent-Cliff Exposure & CMS Drug Spending Portfolio

Cipla (Warren, NJ): 8 reconciled FDA prescription therapies, $92.4M 2024 CMS Part D & Medicaid spend, and $22,031 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterWarren, NJ
Reconciled FDA Portfolio Therapies8
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$92.4M
2024 Medicare Part D Spend$76.3M
2024 Medicaid Spend$16.1M
California HCAI SB 17 FilingsSpecialty launch notice ($22,031 intro WAC)